Advertisement
Advertisement
U.S. markets open in 2 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4100-0.0100 (-0.70%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close1.4200
Open1.4200
Bid1.0100 x 3100
Ask6.8900 x 1400
Day's Range1.3600 - 1.4500
52 Week Range1.1900 - 8.2700
Volume59,502
Avg. Volume77,012
Market Cap56.956M
Beta (5Y Monthly)-0.05
PE Ratio (TTM)N/A
EPS (TTM)-2.6440
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INZY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inozyme Pharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/02/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

    BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET. A replay of the fi

  • GlobeNewswire

    Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

    - Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 – - Liquidity and capital resources as of quarter end funds cash flow requirements into the second quarter of 2024 – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing nove

  • GlobeNewswire

    Inozyme Pharma to Participate in Upcoming Investor Conferences

    BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following investor conferences: The Jefferies London Healthcare Conference. The presentation will take place on Thursday, Novemb

Advertisement
Advertisement